
Asia-Pacific Point-of-Care Diagnostics Market (2025-2032)
The Asia-Pacific Point-of-Care Diagnostics Market is projected to reach $11.80 billion by 2032, at a CAGR of 7.5% from 2025 to 2032.
- Published
- Jan 2025
- Pages
- 200
- Format
- PDF + Excel
- Report ID
- MRHC - 104988
- Base year
- 2024
- 2032 · FORECAST
- $11.80B
- 2032
- $11.80B
- CAGR 2025–2032
- 7.5%
2024 baseline · 2025–2032 forecast at 7.5% CAGR · hover a bar for the value
Key highlights
In 2025, the Consumables Segment is Expected to Dominate the Asia-Pacific Point-of-Care Diagnostics Market
In 2025, the Blood Sample Segment is Expected to Dominate the Asia-Pacific Point-of-Care Diagnostics Market
In 2025, the Blood Glucose Monitoring Segment is Expected to Dominate the Asia-Pacific Point-of-Care Diagnostics Market
In 2025, the Lateral Flow Assays Segment is Expected to Dominate the Asia-Pacific Point-of-Care Diagnostics Market
In 2025, the Hospitals Segment is Expected to Dominate the Asia-Pacific Point-of-Care Diagnostics Market
China: Fastest-growing Country-level Market
Report summary
| Particulars | Details |
|---|---|
| Base Year | 2024 |
| Estimated Year | 2025 |
| Forecast Period | 2025–2032 |
| Market Size (2032) | USD 11.80 billion |
| CAGR (2025–2032) | 7.5% |
| Format | PDF, Excel & Cloud Portal · 200 pages |
| Segments Covered | By Offering: Consumables, Instruments, Software and Services · By Platform: Lateral Flow Assays, Molecular Diagnostics, Other Platforms · By Application: Blood Glucose Monitoring, Infectious Disease Testing Parasitic Infections Testing, Blood-Borne Infections Testing Hepatitis, HIV, Other Blood-Borne Infections, Influenza, Pneumonia, Tuberculosis (TB), Salmonellosis, E. Coli Infections, Pregnancy Testing, Fertility Testing, Prothrombin Time (PT/INR) Testing, Activated Clotting Time (ACT/APTT) Testing · By Sample Type: Blood Sample, Nasopharyngeal Swab, Urine Sample, Saliva Sample, Other Sample Types · By End User: Hospitals, Home Care/Self-Testing, Physician Offices & Ambulatory Care Settings, Diagnostics Laboratories, Other End Users · By Sample |
| Countries Covered | Asia-Pacific (RoAPAC) |
| Key Companies | Abbott Laboratories (U.S.), Siemens Healthineers AG, QuidelOrtho Corporation (U.S.), F. Hoffmann-La Roche Ltd, Danaher Corporation (U.S.), Becton, Dickinson and Company (U.S.), Trinity Biotech plc, Werfen, Nova Biomedical (U.S.), Sekisui Diagnostics, LLC. (U.S.), Thermo Fisher Scientific Inc. (U.S.) |
Report overview
Segments covered: offering, platform, application, sample type, end user, sample. Regions: Asia-Pacific.
Point-of-Care diagnostics (PoC diagnostics), also known as bedside or near-patient testing, refers to medical diagnostic testing conducted near the patient, typically at the location where healthcare is provided. The key characteristic of PoC diagnostics is the ability to deliver rapid results, often within minutes, allowing healthcare providers to make immediate treatment decisions or recommendations based on the test outcomes.
The growth of this market is driven by the increasing prevalence of chronic diseases, innovations in PoC tests, and a lack of skilled technicians for performing lab tests. However, the pricing pressure due to fluctuations in reimbursements restrains the market’s growth. Furthermore, healthcare professionals’ increasing preference for PoC tests over lab tests will offer significant market growth opportunities. However, a lack of awareness regarding the use of PoC devices challenges the market’s growth.
The demand for pathology services has grown significantly in recent years and is expected to grow further during the forecast period. However, the pathology workforce has not increased in line with this demand. Delays in initial diagnosis can lead to delays in treatment. The workforce shortage can be attributed to aging and retiring professionals and the lack of adequate histology programs to train enough new entrants.
According to Medical Futurist, by 2032, the number of active pathologists may drop by 30% compared to 2010 levels. The Chinese Pathologist Association states that there are only 20,000 licensed pathologists in China, a country with a population of over 1.4 billion. Furthermore, there is a growing need for clinical laboratory workers due to their acute shortage. Factors such as laboratory professionals retiring or leaving the profession, the increasing demand for laboratory services, and changes in clinical laboratory science practices due to technological advances contribute to this shortage of skilled professionals. This shortage disrupts the delivery of healthcare services, impacting patients and healthcare providers. Thus, the shortage of skilled professionals leads to delays in diagnosis and treatment, leading to an increased reliance on self-testing. These factors are boosting the adoption of PoC diagnostics, driving the growth of this market.
Many healthcare professionals in hospitals and clinical laboratories prefer using point-of-care diagnostics to diagnose various health conditions promptly. Healthcare professionals are replacing established diagnostic methods (microscopy, pathogen culturing, biochemical testing, conventional polymerase chain reaction (PCR), enzyme-linked immunoassay (ELISA), and other time-consuming diagnostic methods) with new point-of-care diagnostic techniques that provide higher levels of efficiency and reproducibility. As point-of-care diagnostics have superior utility, experts are changing their traditional approaches. This acceptance of point-of-care diagnostics is supporting the research & development efforts of clinical laboratories and other health-services companies in the diagnostics industry. This inclination towards point-of-care methods and practices among physicians drives the growth of the point-of-care diagnostics market.
Report infographic

Table of contents
13 chapters · 115 sections · 200 pages · click to expandSegmental analysis
| Segment | Largest share (2025) | Fastest growth (2025–2032) |
|---|---|---|
| By Offering | Consumables | — |
| By Sample Type | Blood Sample | — |
| By Application | Blood Glucose Monitoring | — |
| By Platform | Lateral Flow Assays | — |
| By End User | Hospitals | — |
By Offering
- The consumables segment is expected to account for the largest share of the Asia-Pacific Point-of-Care Diagnostics Market.
- Factors such as the increasing number of immunoassay and molecular diagnostics tests being performed globally, leading to recurrent purchases of kits and reagents, rise in product approvals, and technological advancements in PoC testing are contributing to the large share of this market.
By Sample Type
- The blood sample segment is expected to account for the largest share of the Asia-Pacific Point-of-Care Diagnostics Market.
- The large market share of this segment is attributed to the availability of a large variety of tests using blood samples, increasing prevalence of various chronic diseases, and increasing consumer awareness regarding the monitoring of chronic diseases.
By Application
- The blood glucose monitoring segment is expected to account for the largest share of the Asia-Pacific Point-of-Care Diagnostics Market.
- The large market share of this segment is attributed to the rising prevalence of diabetes and the growing need for blood glucose monitoring.
- For instance, according to the International Diabetes Federation (IDF), in Southeast Asia, the number of adults with diabetes is estimated to reach 113 million by 2032 from 90 million in 2021.
By Platform
- The lateral flow assays segment is expected to account for the largest share of the Asia-Pacific Point-of-Care Diagnostics Market.
- Lateral flow assays are simple one-step assays that are low-cost devices.
- The major factors contributing to this segment's largest share are the growing prevalence of chronic and infectious diseases, technological innovations, and the advantages of lateral flow assays, such as cost-effectiveness and rapid results.
By End User
- The hospitals segment is expected to account for the largest share of the Asia-Pacific Point-of-Care Diagnostics Market.
- The rising number of hospitals and clinics, increasing demand for point-of-care diagnostics, and increasing healthcare expenditure worldwide are driving the demand for PoC diagnostics.
- Furthermore, the outbreak of the COVID-19 pandemic has resulted in an increased demand for PoC diagnostic kits in hospitals & clinics for the treatment and prevention of COVID-19 infections.
Geographic analysis
Asia-Pacific
Fastest growthThe rising prevalence of infectious & chronic diseases, the growing aging population, and the increasing adoption of self-testing mainly drive the growth of this market. Healthcare spending in China has shown year-on-year growth. According to The World Bank Group, the health expenditure (% of GDP) increased from 4.94% in 2015 to 5.59% in 2020. China: Fastest-growing Country-level Market
Competitive landscape
- Abbott Laboratories (U.S.)
- Siemens Healthineers AG · Germany
- QuidelOrtho Corporation (U.S.)
- F. Hoffmann-La Roche Ltd · Switzerland
- Danaher Corporation (U.S.)
- Becton
- Dickinson and Company (U.S.)
- Trinity Biotech plc · Ireland
- Werfen · Spain
- Nova Biomedical (U.S.)
- Sekisui Diagnostics, LLC. (U.S.)
- Thermo Fisher Scientific Inc. (U.S.)
Frequently asked questions
The Asia-Pacific Point-of-Care market study covers the market sizes & forecasts for types of point-of-care tests used in hospitals, home care/self-testing, physician offices & ambulatory care settings, diagnostics laboratories. The report includes the value analysis of various segments of the Asia-Pacific Point-of-Care at the country/region level.
Cite this report
Meticulous Research. (2025). Asia-Pacific Point-of-Care Diagnostics Market - Opportunity Analysis And Industry Forecast (2025-2032) (Report No. MRHC - 104988). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/product/asia-pacific-point-of-care-diagnostics-market-5671